药品
药物发现
文件夹
药理学
临床试验
药物开发
损耗
医学
计算生物学
内科学
生物信息学
重症监护医学
业务
生物
财务
牙科
作者
Rasmus Jansson‐Löfmark,Markus Fridén,Lassina Badolo,Christine Ahlström,Ian K. Gurrell,Menelas N. Pangalos,Rhys D. O. Jones
标识
DOI:10.1016/j.drudis.2025.104417
摘要
Attrition in drug development continues to be dominated by failure in clinical mid-stage proof-of-concept studies. Successfully demonstrating proof-of-mechanism (PoM) has been reported to be a key factor to improve clinical success. Accurate prediction and testing of PoM are crucial. This analysis of AstraZeneca's portfolio assesses the role of translational PK/PD modelling in predicting clinical PoM. It has found that 83% of compounds had drug exposure-response within a threefold prediction accuracy. Notably, projects with robust PK/PD packages achieved an 85% success rate in PoM, compared with 33% for those with basic packages. This highlights how translational PK/PD modelling can significantly enhance success rates for drugs entering clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI